Floatz logo

et140203 t cells

Hepatoblastoma

Eureka Therapeutics Inc.Cell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

43 Active assets in the Hepatoblastoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB
(+)-VINCRISTINE
University of Birmingham
Phase 3BB
ETOPOSIDE
Children's Oncology Group
Phase 3BB
Eloxatin
Children's Oncology Group
Phase 3BB
Carboplatin
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

et140203 t cells is also rated in:

liver cancerDormant
CCC
Indicative ·
48 / 100
View asset →
HEMNOSDormant
CCC
Indicative ·
48 / 100
View asset →
liver and intrahepatic bile duct neoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →